Skip to content
1887

Journal of Medical Microbiology logo Journal of Medical Microbiology

Volume 75, Issue 4

Dynamic procalcitonin-guided antibiotic stewardship among cancer patients in the UK Open Access

Abstract

Procalcitonin has been recognized as a tool for effective antibiotic stewardship to reduce unnecessary antibiotic use; however, its effectiveness remains unknown in the oncology setting, where infections are common and antibiotics are frequently prescribed.

The utility of procalcitonin for effective antibiotic stewardship in people with solid organ cancers is unknown.

To evaluate the role of procalcitonin dynamics in solid organ cancer patients with suspected bacterial infections in predicting clinical outcomes and guiding antibiotic therapy decisions.

A single-centre evaluation was conducted at the Bristol Haematology and Oncology Centre, studying consecutive admissions of adult patients with solid organ cancer over a 3-month period. In a population in which serum procalcitonin levels were sporadically measured to guide antibiotic therapy, they were measured as standard care on admission and at 48 hours for patients admitted with a suspected bacterial infection. A threshold of 0.25 ng ml was used to distinguish between low and high procalcitonin levels. Cases that had persistently low procalcitonin levels were retrospectively analysed for the potential identification of patients who could have had their antibiotic treatment ceased 48 hours into the antibiotic course.

Seventy-seven cases with procalcitonin readings were recorded. Seventy (90.9%) cases received intravenous antibiotics during admission. Twenty-seven (35.1%) cases had persistently low procalcitonin, defined as <0.25 ng ml on consecutive measurements, interpreted as unlikely to have bacterial infection as suggested from previous literature. No objective microbiological evidence of bacterial infection was observed in these cases. Retrospective clinician reviews of the 27 cases showed antibiotic therapy for 16 of the 27 cases could have been stopped 48 h into the admission, equivalent to a total reduction of up to 83/778 (10.7%) antibiotic days.

Procalcitonin could provide a helpful adjunct for clinicians to consider antibiotic stewardship and help reduce unnecessary antibiotic use in the oncology setting.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): bacterial , cancer , infection , oncology , procalcitonin and stewardship
© 2026 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License. This article was made open access via a Publish and Read agreement between the Microbiology Society and the corresponding author’s institution.
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.002145
2026-04-07
2026-04-22

Metrics

Loading full text...

Full text loading...

/deliver/fulltext/jmm/75/4/jmm002145.html?itemId=/content/journal/jmm/10.1099/jmm.0.002145&mimeType=html&fmt=ahah

References

  1. O’Neill J. Tackling drug-resistant infections globally: final report and recommendations. The review on antimicrobial resistance 2016
     [Google Scholar]
  2. Vijayan AL. Vanimaya Ravindran S, Saikant R, Lakshmi S et al. Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy. J Intensive Care 2017; 5:51 [View Article] [PubMed]
     [Google Scholar]
  3. Schuetz P, Wirz Y, Sager R, Christ-Crain M, Stolz D et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis 2018; 18:95–107 [View Article] [PubMed]
     [Google Scholar]
  4. Russell CD, Fairfield CJ, Drake TM, Turtle L, Seaton RA et al. Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. Lancet Microbe 2021; 2:e354–e365 [View Article] [PubMed]
     [Google Scholar]
  5. Park JH, Suh DH, Kim HJ, Lee YI, Kwak IH et al. Role of procalcitonin in infected diabetic foot ulcer. Diabetes Res Clin Pract 2017; 128:51–57 [View Article] [PubMed]
     [Google Scholar]
  6. Levine AR, Tran M, Shepherd J, Naut E. Utility of initial procalcitonin values to predict urinary tract infection. Am J Emerg Med 2018; 36:1993–1997 [View Article] [PubMed]
     [Google Scholar]
  7. Schuetz P, Beishuizen A, Broyles M, Ferrer R, Gavazzi G et al. Procalcitonin (PCT)-guided antibiotic stewardship: an international experts consensus on optimized clinical use. Clinical Chemistry and Laboratory Medicine (CCLM) 2019; 57:1308–1318 [View Article]
     [Google Scholar]
  8. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009; 302:1059–1066 [View Article] [PubMed]
     [Google Scholar]
  9. Drozdov D, Schwarz S, Kutz A, Grolimund E, Rast AC et al. Procalcitonin and pyuria-based algorithm reduces antibiotic use in urinary tract infections: a randomized controlled trial. BMC Med 2015; 13:104 [View Article] [PubMed]
     [Google Scholar]
  10. Medical Research Council Health Research Authority decision tool [Internet]. London: NHS Health Research Authority; 2017 https://www.hra-decisiontools.org.uk/research/ accessed 1 July 2021
  11. Department of Health and Social Care Tackling antimicrobial resistance 2019 to 2024: The UK’s five-year national action plan. HM government; 2019
  12. Giuliano C, Patel CR, Kale-Pradhan PB. A guide to bacterial culture identification and results interpretation. P T 2019; 44:192–200 [PubMed]
     [Google Scholar]
  13. Doern GV, Carroll KC, Diekema DJ, Garey KW, Rupp ME et al. Practical guidance for clinical microbiology laboratories: a comprehensive update on the problem of blood culture contamination and a discussion of methods for addressing the problem. Clin Microbiol Rev 2019; 33:10–128 [View Article] [PubMed]
     [Google Scholar]
  14. Butler CC, Rollnick S, Pill R, Maggs-Rapport F, Stott N. Understanding the culture of prescribing: qualitative study of general practitioners’ and patients’ perceptions of antibiotics for sore throats. BMJ 1998; 317:637–642 [View Article] [PubMed]
     [Google Scholar]
  15. Kohut MR, Keller SC, Linder JA, Tamma PD, Cosgrove SE et al. The inconvincible patient: how clinicians perceive demand for antibiotics in the outpatient setting. Fam Pract 2020; 37:276–282 [View Article] [PubMed]
     [Google Scholar]
  16. van der Zande MM, Dembinsky M, Aresi G, van Staa TP. General practitioners’ accounts of negotiating antibiotic prescribing decisions with patients: a qualitative study on what influences antibiotic prescribing in low, medium and high prescribing practices. BMC Fam Pract 2019; 20:172 [View Article] [PubMed]
     [Google Scholar]
  17. Krumholz HM. Variations in health care, patient preferences, and high-quality decision making. JAMA 2013; 310:151 [View Article]
     [Google Scholar]
  18. Westwood M, Ramaekers B, Whiting P, Tomini F, Joore M et al. Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis. Health Technol Assess 2015; 19:1–236 [View Article]
     [Google Scholar]
  19. Kip MMA, Kusters R, IJzerman MJ, Steuten LMG. A PCT algorithm for discontinuation of antibiotic therapy is a cost-effective way to reduce antibiotic exposure in adult intensive care patients with sepsis. J Med Econ 2015; 18:944–953 [View Article] [PubMed]
     [Google Scholar]
  20. Covington EW, Roberts MZ, Dong J. Procalcitonin monitoring as a guide for antimicrobial therapy: a review of current literature. Pharmacotherapy 2018; 38:569–581 [View Article]
     [Google Scholar]
  21. Baker C, Mansfield Z. Cancer statistics for England. House of commons library 2023
     [Google Scholar]
  22. Forman D, Stockton D, Møller H, Quinn M, Babb P et al. Cancer prevalence in the UK: results from the EUROPREVAL study. Ann Oncol 2003; 14:648–654 [View Article] [PubMed]
     [Google Scholar]
  23. Maddams J, Utley M, Møller H. Projections of cancer prevalence in the United Kingdom, 2010-2040. Br J Cancer 2012; 107:1195–1202 [View Article] [PubMed]
     [Google Scholar]
  24. Kornepati AVR, Vadlamudi RK, Curiel TJ. Programmed death ligand 1 signals in cancer cells. Nat Rev Cancer 2022; 22:174–189 [View Article] [PubMed]
     [Google Scholar]
  25. Jiang S, Geng S, Chen Q, Zhang C, Cheng M et al. Effects of concomitant antibiotics use on immune checkpoint inhibitor efficacy in cancer patients. Front Oncol 2022; 12:823705 [View Article]
     [Google Scholar]
  26. Lurienne L, Cervesi J, Duhalde L, de Gunzburg J, Andremont A et al. NSCLC immunotherapy efficacy and antibiotic use: a systematic review and meta-analysis. J Thorac Oncol 2020; 15:1147–1159 [View Article] [PubMed]
     [Google Scholar]
  27. Thompson NA, Stewart GD, Welsh SJ, Doherty GJ, Robinson MJ et al. The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy. BMC Cancer 2022; 22:99 [View Article]
     [Google Scholar]
  28. Zhao Z, Li X, Zhao Y, Wang D, Li Y et al. Role of C-reactive protein and procalcitonin in discriminating between infectious fever and tumor fever in non-neutropenic lung cancer patients. Medicine (Baltimore) 2018; 97:e11930 [View Article]
     [Google Scholar]
  29. Chaftari P, Qdaisat A, Chaftari A-M, Maamari J, Li Z et al. Prognostic value of procalcitonin, c-reactive protein, and lactate levels in emergency evaluation of cancer patients with suspected infection. Cancers (Basel) 2021; 13:4087 [View Article] [PubMed]
     [Google Scholar]
  30. Morgan JE, Phillips B. PAnTher Cub: procalcitonin-guided antibiotic therapy for febrile neutropenia in children and young people with cancer - a single-arm pilot study. BMJ Paediatr Open 2022; 6:e001339 [View Article] [PubMed]
     [Google Scholar]
  31. Gavazzi G, Drevet S, Debray M, Bosson JL, Tidadini F et al. Procalcitonin to reduce exposure to antibiotics and individualise treatment in hospitalised old patients with pneumonia: a randomised study. BMC Geriatr 2022; 22:965 [View Article] [PubMed]
     [Google Scholar]
  32. Lhopitallier L, Kronenberg A, Meuwly J-Y, Locatelli I, Mueller Y et al. Procalcitonin and lung ultrasonography point-of-care testing to determine antibiotic prescription in patients with lower respiratory tract infection in primary care: pragmatic cluster randomised trial. BMJ 2021; 374:n2132 [View Article] [PubMed]
     [Google Scholar]
  33. Ichikawa K, Watanabe S, Miura S, Ohtsubo A, Shoji S et al. Prognostic significance of procalcitonin in small cell lung cancer. Transl Lung Cancer Res 2022; 11:43–52 [View Article] [PubMed]
     [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.002145
Loading
Dynamic procalcitonin-guided antibiotic stewardship among cancer patients in the UK
J. Med. Microbiol. 75, 002145 (2026); https://doi.org/10.1099/jmm.0.002145
/content/journal/jmm/10.1099/jmm.0.002145
/content/journal/jmm/10.1099/jmm.0.002145
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An error occurred
Approval was partially successful, following selected items could not be processed due to error